#1 Clinical Trials Search in Europe

Cefiderocol

Cefiderocol is a novel siderophore cephalosporin antibiotic developed for treating infections caused by Gram-negative bacteria, including those resistant to other antibiotics. This article summarizes key information from clinical trials evaluating cefiderocol’s effectiveness and safety for various types of infections.

Table of Contents

What is Cefiderocol?

Cefiderocol is a new type of antibiotic developed to treat serious infections caused by Gram-negative bacteria. It’s also known by the brand name FETROJA® and was previously called S-649266 during its development[2]. Cefiderocol belongs to a class of antibiotics called cephalosporins, but it has a unique feature that makes it effective against bacteria that are resistant to other antibiotics[1].

How Does Cefiderocol Work?

Cefiderocol uses a special mechanism to enter bacteria cells. It acts like a “Trojan horse” by attaching to iron molecules, which bacteria need to survive. This allows cefiderocol to sneak past the bacteria’s defenses and enter the cell. Once inside, it kills the bacteria by preventing them from building their cell walls properly[1]. This unique method makes cefiderocol effective against many types of bacteria, including those that have become resistant to other antibiotics.

What Conditions Does Cefiderocol Treat?

Cefiderocol is approved to treat several types of serious bacterial infections, including:

  • Complicated urinary tract infections (cUTIs): These are infections in the urinary system that are more difficult to treat, often involving the kidneys (also called pyelonephritis)[2].
  • Hospital-acquired bacterial pneumonia (HABP): This is a lung infection that patients get while in the hospital[3].
  • Ventilator-associated bacterial pneumonia (VABP): This is a type of pneumonia that occurs in patients who are on breathing machines[3].
  • Healthcare-associated bacterial pneumonia (HCABP): This is pneumonia that develops in people who have frequent contact with healthcare settings[3].

Cefiderocol is particularly useful for treating infections caused by bacteria that are resistant to many other antibiotics, including a group called carbapenem-resistant bacteria[1].

Clinical Studies on Cefiderocol

Several clinical trials have been conducted to test the effectiveness and safety of cefiderocol:

  • A study compared cefiderocol to another antibiotic called imipenem/cilastatin for treating complicated urinary tract infections. The study looked at how well the drug eliminated bacteria and improved symptoms[2].
  • Another study compared cefiderocol to meropenem (another antibiotic) for treating hospital-acquired pneumonia, ventilator-associated pneumonia, and healthcare-associated pneumonia. This study primarily looked at survival rates of patients 14 days after starting treatment[3].
  • A study called PERSEUS is examining how cefiderocol is used in real-world settings to treat various Gram-negative infections[1].

Administration and Dosage

Cefiderocol is given as an intravenous infusion, which means it’s administered directly into a vein. The typical dose is 2 grams every 8 hours, but this can vary depending on the patient’s kidney function[3]. The infusion usually takes about 3 hours to complete. The duration of treatment can range from 7 to 14 days, depending on the type and severity of the infection[2].

Safety and Side Effects

Like all medications, cefiderocol can cause side effects. In clinical trials, researchers carefully monitored patients for any adverse reactions. Common side effects may include diarrhea, nausea, and reactions at the infusion site. More serious side effects are possible but less common. It’s important to note that the benefits of treating severe infections often outweigh the risks of side effects[3].

Ongoing Research

Research on cefiderocol is ongoing to better understand how it works in different patient groups and situations:

  • A study is looking at how cefiderocol behaves in patients on extracorporeal membrane oxygenation (ECMO), a life support machine that oxygenates blood outside the body[4].
  • Another study is examining how cefiderocol works in patients receiving continuous renal replacement therapy (CRRT), a type of dialysis for patients with kidney failure[5].
  • Researchers are also studying cefiderocol in patients with cystic fibrosis who have lung infections[6].
  • A study is investigating how cefiderocol interacts with another medication called midazolam[7].
  • Another study is looking at how cefiderocol works when combined with a new drug called xeruborbactam[8].

These ongoing studies will help doctors better understand how to use cefiderocol effectively and safely in different types of patients and situations.

Aspect Details
Drug Name Cefiderocol (also known as S-649266, FETROJA®)
Drug Class Siderophore cephalosporin antibiotic
Target Pathogens Gram-negative bacteria, including carbapenem-resistant strains
Indications Studied Complicated urinary tract infections, hospital-acquired pneumonia, ventilator-associated pneumonia, healthcare-associated pneumonia
Administration Intravenous infusion, typically 2g every 8 hours (dose adjustments for renal function)
Efficacy Comparable to standard-of-care antibiotics in clinical trials
Safety Profile Generally well-tolerated; common side effects include gastrointestinal symptoms
Special Populations Studies ongoing in patients with renal impairment, on ECMO, and with cystic fibrosis
Potential Advantages Active against multidrug-resistant pathogens, novel mechanism of action

FAQ

  • What types of infections can cefiderocol treat? Cefiderocol has been studied for treating complicated urinary tract infections, hospital-acquired pneumonia, ventilator-associated pneumonia, and other serious Gram-negative bacterial infections.
  • How is cefiderocol administered? Cefiderocol is given as an intravenous infusion, typically 2 grams every 8 hours. The dosage may be adjusted based on kidney function.
  • How effective is cefiderocol compared to other antibiotics? Clinical trials have shown cefiderocol to be similarly effective to antibiotics like imipenem/cilastatin and meropenem for treating various Gram-negative infections.
  • What are the most common side effects of cefiderocol? Common side effects may include diarrhea, nausea, and other gastrointestinal symptoms. Serious allergic reactions are possible but rare.
  • Is cefiderocol safe for patients with kidney problems? Cefiderocol can be used in patients with kidney issues, but the dose may need to be adjusted. Studies have looked at its use in patients on dialysis and other forms of renal replacement therapy.

Ongoing Clinical Trials on Cefiderocol

  • Study on the Effectiveness and Safety of 7 vs. 14 Days of Antibiotic Treatment with Meropenem for Patients with Pseudomonas Aeruginosa Blood Infection

    Recruiting

    3 1 1 1
    Investigated drugs:
    Spain

  • Study on Cefiderocol for Treating Gram-negative Bacterial Infections in Hospitalized Infants Under 3 Months

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Greece Spain

Glossary

  • Gram-negative bacteria: A class of bacteria that do not retain crystal violet stain in the Gram staining method. They are a common cause of serious infections, especially in healthcare settings.
  • Cephalosporin: A class of antibiotics derived from the fungus Acremonium. Cefiderocol is a new type of cephalosporin with a unique mechanism of action.
  • Siderophore: A small, high-affinity iron-chelating compound secreted by microorganisms. Cefiderocol uses a siderophore component to penetrate bacterial cell walls.
  • Complicated urinary tract infection: A urinary tract infection associated with factors that increase the likelihood of acquiring infection or decrease the effectiveness of treatment.
  • Hospital-acquired pneumonia: Pneumonia that develops 48 hours or more after hospital admission, not incubating at the time of admission.
  • Ventilator-associated pneumonia: Pneumonia that develops in patients who have been on mechanical ventilation for at least 48 hours.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Microbiological eradication: The elimination of disease-causing microorganisms from a site of infection, as determined by laboratory testing.
  • Clinical cure: The resolution or substantial improvement of signs and symptoms of an infection, such that no additional antibiotic therapy is required.
  • All-cause mortality: Deaths from any cause during a specified time period in a study.

References

  1. https://clinicaltrials.gov/study/NCT05789199
  2. https://clinicaltrials.gov/study/NCT02321800
  3. https://clinicaltrials.gov/study/NCT03032380
  4. https://clinicaltrials.gov/study/NCT04995835
  5. https://clinicaltrials.gov/study/NCT05373615
  6. https://clinicaltrials.gov/study/NCT05314764
  7. https://clinicaltrials.gov/study/NCT05395104
  8. https://clinicaltrials.gov/study/NCT06547554